Abstract:Hemiparkinsonism duration in patients with Parkinson's disease (PD) is a key time window to study early pathology of PD. We aimed to comprehensively explore the alterations of deformation and structural network in PD patients with hemiparkinsonism, which could potentially disclose the early biomarker for PD. Thirty-one PD patients with hemiparkinsonism and 37 age- and gender- matched normal controls were included in the present study. First of all, we normalized the left hemisphere of structural images as the contralateral side to the affected limbs. Deformation-based morphometry (DBM) was conducted to evaluate the brain atrophy and/or enlargement. structural networks were constructed by thresholding gray matter volume correlation matrices of 116 regions and analyzed using graph theoretical approaches (e.g., small-worldness, global, and nodal measures). Significantly decreased deformation values were observed in the temporoparietal regions like bilateral middle temporal gyri, ipsilateral precuneus and contralateral Rolandic operculum extending to supramarginal and postcentral gyri. Lower deformation values in contralateral middle temporal gyrus were negatively correlated with higher motor impairment which was dominated by akinesia/rigidity. Moreover, nodal reorganization of structural network mainly located in frontal, temporal, subcortex and cerebellum was bilaterally explored in PD patients with hemiparkinsonism. Increased nodal properties could be commonly observed in frontal lobes. Disruption of subcortex including basal ganglia and amygdala was detected by nodal local efficiency and nodal clustering coefficient. Twelve hubs, mainly from paralimbic-limbic and heteromodal networks, were disrupted and, alternatively, 14 hubs, most of which were located in frontal lobes, were additionally detected in PD patients with hemiparkinsonism. In conclusion, during hemiparkinsonism period, mild brain atrophy in the temporoparietal regions and widespread reorganization of structural network, e.g., enhanced frontal function and disruption of basal ganglia nodes, occurred in both hemispheres. With our data, we can also argue that MTG contralateral to the affected limbs (expressing clinically verified brain atrophy) might be a potential living biomarker to monitor disease progression. Therefore, the combination of DBM and structural network analyses can provide a comprehensive and sensitive evaluation for potential pathogenesis of early PD patients with hemiparkinsonism.

Unraveling neurotransmitter changes in de novo GBA-related and idiopathic Parkinson's disease

Disrupted morphological grey matter networks in early-stage Parkinson’s disease

Disentangling gray matter atrophy and its neurotransmitter architecture in drug-naïve Parkinson's disease: an atlas-based correlation analysis

Spatiotemporal Neurodegeneration of the Substantia Nigra and Its Connecting Cortex and Subcortex in Parkinson's Disease.

Greater loss of white matter integrity in postural instability and gait difficulty subtype of Parkinson's disease.

Free-Water Imaging of the Substantia Nigra in GBA Pathogenic Variant Carriers

Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease

Synaptic vesicle endocytosis deficits underlie GBA-linked cognitive dysfunction in Parkinson′s disease and Dementia with Lewy bodies

Characterization of a pathogenic variant in GBA for Parkinson’s disease with mild cognitive impairment patients

Quantitative dopamine transporter imaging assessment in Parkinson's disease patients carrying GBA gene mutations compared with idiopathic PD patients: A case-control study

GBA1 mutations alter neuronal firing and structure, regulating VGLUT2 and CRYAB in dopamine neurons

GABAergic imbalance in Parkinson's disease-related depression determined with MEGA-PRESS

Molecular Features of Parkinson's Disease in Patient‐Derived Midbrain Dopaminergic Neurons

Brain Atrophy and Reorganization of Structural Network in Parkinson's Disease with Hemiparkinsonism

Dilated Perivascular Space in the Midbrain May Reflect Dopamine Neuronal Degeneration in Parkinson's Disease.

Unveiling MRI markers for Parkinson's Disease: GABAergic dysfunction and cortical changes

Disrupted topological organization of resting-state functional brain networks in Parkinson's disease patients with glucocerebrosidase gene mutations

Mutational Spectrum and Clinical Features of GBA1 Variants in a Chinese Cohort with Parkinson’s Disease

Large-scale proteomics analysis of five brain regions from Parkinson’s disease patients with a GBA1 mutation

Differences in gray matter atrophy and functional connectivity between motor subtypes of Parkinson's disease

Grey Matter Abnormalities in Parkinson's Disease: a Voxel-Wise Meta-Analysis.